Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial
Alexander M.M. Eggermont(University Medical Center Utrecht), Alessandro Testori(European Organisation for Research and Treatment of Cancer), Dirk Schadendorf(National Center for Tumor Diseases), Elisabetta Pennachioli(European Institute of Oncology), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Lars Bastholt(Odense University Hospital), Sandrine Marréaud(European Organisation for Research and Treatment of Cancer), F. Grange(Hôpital Robert-Debré), Peter Dziewulski(Broomfield Hospital), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Alexander C. J. van Akkooi(The University of Sydney), Rainer Hofman‐Wellenhof(Medical University of Graz), Ernest Marshall(Whiston Hospital), Stefan Suciu(St James's University Hospital), François Salès(Institut Jules Bordet), Alessandro Marco Minisini, Caroline Robert(Institut Gustave Roussy), Maria Marples(Leeds Teaching Hospitals NHS Trust), Catherine Lok(Centre Hospitalier Universitaire Amiens-Picardie), Oliver Bechter(Universitair Ziekenhuis Leuven), Jean-Jacques Grob(Aix-Marseille Université), Michal Kiciński(European Organisation for Research and Treatment of Cancer)
Cited by 14
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k